Singapore, March 30 -- Hong Kong headquartered Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and Tenacia Biotechnology (Hong Kong) Co., a commercial-stage biopharmaceutical company dedicated to developing innovative therapeutics for patients with underserved neurological disorders, have announced that, building on the productive collaboration over the past year, the two parties will further expand and deepen AI-driven R&D collaboration.

In the initial phase of the collaboration launched in March 2025, the companies' combined Insilico's cutting-edge generative AI drug discovery platform, Pharma.AI, and deep drug discovery expertise with Tenacia's specialised scientific insights a...